Fresh analysis reveals that individuals who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who halt conventional diet and exercise regimens.
Findings released in a major medical journal shows that while obese people can lose about a fifth of their body weight while using the jabs, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users purchasing such drugs should be aware of the danger of quick rebound weight gain when the treatment ends," warns researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting weight within about one and a half years.
Analyzing Approaches
The research, which reviewed 37 of trials involving thousands of patients, contrasted the results of these new drugs with other pills.
Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically experience a less rapid creep back—perhaps 100 grams monthly—once they finish.
Understanding the Quick Regain
Doctors believe the way of the injections is key to understanding the heightened weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
The NHS recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts say that, considering the significant potential of weight regain, the treatment might need to be ongoing.
This view is echoed by pharmaceutical companies, who say that the results "underscore the long-term character of obesity," similar to managing diseases like high blood pressure.
Patient Accounts
People who have discontinued the medication describe a powerful resurgence of cravings.
"I experienced something activating and I was suddenly starving," said an individual.
This challenge is compounded if patients have not adopted permanent lifestyle or habit changes during treatment.
Widespread Interest
Figures suggest that a significant number of people in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, researchers emphasize that while these medications are powerful agents for weight loss, they are not a permanent cure and lasting health benefits relies on integrated behavioural management.
